

It is with the greatest honor and a profound sense of responsibility that I have succeeded Professor Masaki Nio as President of the Japanese Study Group on Pancreaticobiliary Maljunction (JSGPBM).
During my tenure at Tokushima University, I had the privilege of serving as a secretary general of JSGPBM for more than two decades. I am deeply grateful for the invaluable experience, knowledge, and friendships I have gained throughout those years. Drawing upon these experiences and relationships to the fullest extent, I am determined to build upon the distinguished traditions and aspirations established by our predecessors and to devote myself wholeheartedly to the continued advancement and further development of the JSGPBM.
A Legacy of Nearly Five Decades
The history of our Study Group dates back to 1978, when the “Committee for Establishing Diagnostic Criteria for Pancreaticobiliary Maljunction” was convened under the leadership of the late Professor Nobuhiko Komi of Tokushima University, in conjunction with the 15th Annual Meeting of the Japanese Society of Pediatric Surgeons. On the occasion of its 30th meeting, the name was changed to the “Japanese Study Group on Pancreaticobiliary Maljunction,” the name by which it is known today. Over nearly half a century, the JSGPBM has consistently pursued advances in the diagnosis, pathophysiological understanding, and standardized management of pancreaticobiliary maljunction (PBM), producing a number of landmark achievements.
Major Achievements of the Study Group
1987 — Establishment of the first diagnostic criteria for PBM
Under the leadership of Professor Takuji Todani, the first diagnostic criteria for PBM were established. These criteria were subsequently revised in 1990 and again in 2013, culminating in the current diagnostic criteria for PBM.
1997 — Publication commemorating the 20th anniversary
To commemorate the 20th anniversary of the JSGPBM “Pancreaticobiliary Maljunction: Its Consensus and Controversies” was published under the supervision of the late Professor Nobuhiko Komi and edited by Professor Takahiko Funabiki.
2012 — Publication of clinical practice guidelines
Under the leadership of Professor Terumi Kamisawa, the “Clinical Practice Guidelines for Pancreaticobiliary Maljunction” was published.
2016 — Establishment of diagnostic and therapeutic standards for congenital biliary dilatation (CBD)
Through a research project supported by the Health and Labour Sciences Research Grants for Research, led by Professor Masaki Nio, diagnostic criteria, diagnostic and therapeutic guidelines, and a severity classification for CBD were established.
2017 — Publication commemorating four decades of progress
Under the leadership of Professor Kenichiro Kaneko, “Forty Years of Pancreaticobiliary Maljunction: A Chronicle Through Clinical Episodes” was published, documenting the remarkable evolution of our understanding and clinical management of this disease.
2024 — Revision of the clinical practice guidelines
Under the leadership of Professor Masayuki Otsuka, the revised “Clinical Practice Guidelines for Pancreaticobiliary Maljunction and Congenital Biliary Dilatation” was published, incorporating the latest advances in diagnosis, treatment, and scientific knowledge.
These accomplishments represent the culmination of the unwavering dedication of successive presidents and members of the JSGPBM, as well as the passion and commitment of those who pioneered this field. They constitute an invaluable intellectual legacy and one of the greatest treasures of the JSGPBM.
Challenges and Priorities for the Future
Building upon this distinguished history, I believe that the JSGPBM must now take decisive steps to meet the challenges of the next generation. I consider the following five areas to be of particular importance.
1. Elucidation of the Molecular Pathogenesis and Carcinogenic Mechanisms of PBM
A deeper understanding of the molecular mechanisms underlying carcinogenesis in PBM and the biological processes involved in the development and progression of biliary tract cancer is an important scientific challenge, with implications extending well beyond PBM itself.
To advance this field, I believe that the JSGPBM should take the initiative in planning and promoting large-scale multicenter collaborative studies, bringing together clinical and basic researchers from across Japan and, ultimately, from around the world.
2. Establishment of a Globally Recognized Classification System and International Clinical Practice Guidelines
The revision and international standardization of the classification of PBM and CBD have long remained important issues. I believe that now is the time to address this challenge with renewed determination and to establish a classification system that will be recognized and accepted worldwide.
Achieving this goal will require us to bring together the collective wisdom and expertise of specialists throughout Japan while simultaneously strengthening international collaboration. One important initiative in this regard is international collaborative research with leading investigators overseas, including Professor Qian Dong, President of the Institute of Digital Medicine and Computer-Assisted Surgery at Qingdao University, China, with whom I currently have the honor of serving as Chief Expert. Through such international partnerships, we hope to foster a common scientific language and establish globally applicable standards for the diagnosis and management of PBM and CBD.
3. Expansion and Effective Utilization of Our Valuable Clinical Database
The clinical database that the JSGPBM has accumulated over many years represents an extraordinary and unique academic asset. Going forward, it will be essential not only to further increase the number of registered cases but also to establish a comprehensive database capable of elucidating long-term outcomes according to disease severity. Furthermore, we should actively utilize these data for long-term follow-up studies and apply them to the development and validation of new classification systems. By enhancing both the quantity and quality of our database and translating these resources into meaningful clinical research, we can further strengthen the scientific foundation of the JSGPBM.
4. Pursuing Designation of CBD as an Intractable Disease
Obtaining official designation of CBD as an intractable disease under the current disease concept is unlikely to be straightforward. Accordingly, we are proposing a new disease concept, namely “CBD associated with congenital intrahepatic bile duct stenosis and dilatation.” Through the Diagnostic Criteria Committee, we are currently working to establish its definition, diagnostic criteria, and severity classification. In parallel, we plan to conduct a nationwide epidemiological survey to clarify the medical and social significance of this disease concept. Through these efforts, we hope to establish a robust scientific basis for seeking its designation as an intractable disease.
5. Nurturing the Next Generation and Strengthening Outreach to Encourage the Participation of Young Professionals and Researchers
The continued vitality and sustainable development of the JSGPBM depend fundamentally upon the active participation of the next generation of physicians and researchers. PBM is a rare disease, yet it presents profound and fascinating medical and scientific questions. It is therefore essential that we communicate its intellectual appeal more widely and inspire the curiosity and aspirations of younger generations. We must actively disseminate the activities and scientific achievements of the JSGPBM, deepen the understanding and interest of young healthcare professionals and researchers, and encourage their participation and engagement. Such outreach will not only foster the next generation of investigators but also contribute to expanding case registration and strengthening the foundation for future collaborative research.
Looking Toward the Future
The JSGPBM has reached its present stature through the passion and dedication of pioneers such as the late Professor Nobuhiko Komi, together with the tireless efforts of generations of members who have carried this field forward. It is my profound conviction that my responsibility as President is to honor this rich history and enduring tradition while opening a new chapter for the future. Although my contribution may be modest, I will devote myself wholeheartedly to bringing together the wisdom, experience, and energy of our members and to advancing the JSGPBM to even greater heights. At the same time, I will strive to contribute to further progress in the diagnosis, treatment, and scientific understanding of PBM and CBD. I sincerely ask all members of the Study Group, as well as all those visiting this website, for your continued understanding, cooperation, and steadfast support of our activities.
Together, building upon the achievements of the past and embracing the possibilities of the future, let us carry forward the legacy entrusted to us and open a new era in the study and management of PBM.
September 2026
Mitsuo Shimada, MD, PhD, FACS.
President
Japanese Study Group on Pancreaticobiliary Maljunction